Rhythm Pharmaceuticals, Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. This is an annual filing; it does not provide a clear standalone fourth-quarter financial summary. Unless noted otherwise, dollar amounts below are in millions.
Business context
Rhythm is a commercial-stage biopharmaceutical company focused on IMCIVREE (setmelanotide), a treatment for severe obesity and hyperphagia associated with rare MC4R-pathway diseases. In 2022, IMCIVREE was approved in the United States for Bardet-Biedl syndrome (BBS), in addition to certain genetic deficiencies, and gained European Commission authorization for BBS. The company continued commercialization and clinical development, while reporting that it had generated less than $25 million in cumulative product sales to date.
Financial results and liquidity
| Metric | FY2022 | FY2021 | Change / context |
|---|---|---|---|
| Product revenue, net | $16.9 | $3.2 | Up 435%; 85% of 2022 product revenue came from the United States. |
| License revenue | $6.8 | — | Recognized from the RareStone agreement; not recurring product sales. |
| Total revenue | $23.6 | $3.2 | Up 649%. |
| Cost of sales | $2.1 | $0.6 | Included royalties and amortization; much earlier manufacturing cost had been expensed as R&D. |
| Research and development | $108.6 | $104.1 | Up 4%. |
| Selling, general and administrative | $92.0 | $68.5 | Up 34%, reflecting commercial expansion and higher staffing and operating costs. |
| Operating loss | $(179.2) | $(170.1) | Loss widened despite increased revenue. |
| Net loss | $(181.1) | $(69.6) | 2021 benefited from a nonrecurring $100 million gain on sale of a priority review voucher. |
| Net loss per share, diluted | $(3.47) | $(1.40) | Weighted-average shares increased to 52.1 million from 49.6 million. |
| Net cash used in operating activities | $(173.4) | $(146.0) | Operating cash use increased. |
At year-end, cash and cash equivalents were $127.7 million and short-term investments were $205.6 million, totaling $333.3 million. Current assets were $354.2 million and current liabilities were $39.8 million. Management expected year-end cash and investments to fund operations into 2025, while cautioning that future funding may still be required. The company reported an accumulated deficit of $710.1 million and expects continued operating losses.
Financing included $131.1 million net proceeds from a 2022 common-stock offering and $72.3 million net proceeds under a revenue-interest financing agreement. The agreement is recorded as a $75.8 million deferred royalty obligation, plus a $1.3 million derivative liability at year-end; it entitles the investor to tiered royalties on revenue and includes minimum-payment, maturity, and change-of-control provisions. The remaining $25 million financing tranche was contingent on achieving a sales milestone.
Material changes and developments
- Product revenue grew from an early commercialization base; 2022 included U.S. BBS launch activity and initial sales in additional international markets.
- Net loss increased substantially year over year, principally because 2021 included the $100 million voucher-sale gain, alongside higher 2022 operating expenses.
- Cash and investments rose to $333.3 million from $294.9 million, supported by equity issuance and the revenue-interest financing; operating cash use also increased.
- In February 2023, after year-end, Rhythm acquired Xinvento B.V. for $5 million at closing, with up to $206 million in contingent development, regulatory and commercial milestone payments. Xinvento is developing candidates for congenital hyperinsulinism.
Outlook, commentary and key risks
Management planned to advance setmelanotide trials in hypothalamic obesity, additional genetic indications, younger pediatric patients, and a weekly formulation. The filing described a Phase 3 hypothalamic-obesity trial initiated in early 2023, anticipated pediatric topline data during 2023, and expected weekly-formulation trial topline data in the second half of 2023. The company also outlined planned market launches in Europe and continued work toward Canadian access. No quantitative revenue or earnings guidance was provided.
Key risks include continued losses and potential need for capital; uncertain reimbursement and market uptake in very small patient populations; clinical-trial, regulatory and safety uncertainty; reliance on external manufacturers and trial providers; and dependence on setmelanotide as the principal commercial product and development program. Management described setmelanotide as generally tolerated in trials, while noting adverse events including skin hyperpigmentation, injection-site reactions, nausea and vomiting. The revenue-interest financing reduces future cash flows available for operations. The company’s termination of its RareStone China license for alleged material breaches was disputed by RareStone; the disagreement could affect development and commercialization in covered markets. The filing reported no material legal proceedings.
Important facts for investors to verify
- Track product sales, patient identification, reimbursement access and geographic revenue mix; 2022 product revenue was $16.9 million, while total revenue also included $6.8 million of RareStone license revenue.
- Assess cash consumption against the stated runway into 2025, the contingent $25 million financing tranche, and the royalty and minimum-payment terms of the revenue-interest agreement.
- Monitor enrollment, readouts and regulatory outcomes for the hypothalamic-obesity, EMANATE, pediatric and weekly-formulation programs; early or interim results may differ from final results.
- Follow the RareStone license dispute and the integration, development costs and contingent milestone exposure associated with the Xinvento acquisition.
- Confirm future commercialization costs, manufacturing capacity and the degree to which the company can reduce its reliance on external funding.